TY - JOUR
T1 - What is the evidence for antipsychotic medication and alternative psychosocial interventions for people with acute, non-affective psychosis?
AU - Jauhar, Sameer
AU - Lawrie, Stephen M
N1 - Funding Information:
SJ is funded by a JMAS Sim fellowship from the Royal College of Physicians (Edinburgh) and National Institute for Health Research Biomedical Research Centre at South London and Maudsley National Health Service Foundation Trust and King's College London.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/1/31
Y1 - 2022/1/31
N2 - In this Personal View, we critically appraise and summarise evidence for antipsychotic drugs and alternatives to drug treatment, with a focus on people in their first episode or acute relapses of schizophrenia and related conditions within the first 5–10 years of illness. There is a large body of generally moderate quality evidence from randomised controlled trials for antipsychotics in both treating acute psychosis and reducing relapse, in thousands of people in their first episode and in established illness. There is a much smaller evidence base, of generally low quality, in a few hundred people, for potential benefits of non-drug interventions, such as cognitive behavioural therapy, Open Dialogue, Soteria, and psychoanalytic psychotherapy.
AB - In this Personal View, we critically appraise and summarise evidence for antipsychotic drugs and alternatives to drug treatment, with a focus on people in their first episode or acute relapses of schizophrenia and related conditions within the first 5–10 years of illness. There is a large body of generally moderate quality evidence from randomised controlled trials for antipsychotics in both treating acute psychosis and reducing relapse, in thousands of people in their first episode and in established illness. There is a much smaller evidence base, of generally low quality, in a few hundred people, for potential benefits of non-drug interventions, such as cognitive behavioural therapy, Open Dialogue, Soteria, and psychoanalytic psychotherapy.
U2 - 10.1016/S2215-0366(21)00293-5
DO - 10.1016/S2215-0366(21)00293-5
M3 - Editorial
SN - 2215-0366
VL - 9
SP - 253
EP - 260
JO - The Lancet Psychiatry
JF - The Lancet Psychiatry
IS - 3
ER -